Pergamon

Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 22, pp. 2647-2650, 1996

0960-894X/96 $15.00 + 0.00

PII: S0960-894X(96)00487-8

2-AMINOALCOHOL IMMUNOSUPPRESSANTS: STRUCTURE-ACTIVITY RELATIONSHIPS

Ryoji Hirose, Norimitsu Hamamichi[a], Yuuki Kitao[b], Tohru Matsuzaki[b], Kenji Chiba[c], and Tetsuro Fujita[a]*

Research Laboratory, Taito Co., Ltd., 1-26 Higashi Shiriike-Shinmachi, Nagata-ku, Kobe 653, Japan

[a]*Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge Hirakata Osaka 573-01, Japan*

[b]*Faculty of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-01, Japan*

[c]*Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., 7-25 Koyata 3-chome, Irumashi, Saitama 358, Japan*

Abstract: The 2-aminoalcohol series of immunosuppressants showed a bell-shaped relationship between the activity and the carbon number. The (*R*)-isomers were more potent than the (*S*)-isomers, and (*R*)-2-aminohexadecanol displayed comparably activity to a potent immunosuppressant, FTY720.

After the isolation of the immunosuppressant ISP-I[1] (**1**: myriocin[2], thermozymocidin[3]) from the culture broth of *Isaria sinclairii*, its structural simplification and modification led to the identification of 2-alkyl-2-aminopropane-1,3-diol (**2**)[4] as the key basic structure for the immunosuppressive activity. Furthermore, introduction of a phenyl ring into the hydrophobic part afforded a potent immunosuppressant, FTY720 (**3**)[5]. Recently, modification of the hydrophilic part of **2** has indicated that 2-aminoalcohol (**4**)[6] is the minimum basic structure for the biological activity.

In this paper, we describe the structure-activity relationships of 2-aminoalcohols of defined absolute configuration at C-2.



ISP-I (**1**: myriocin, thermozymocidin)



2



FTY720 (**3**)



4

a: n= 10, **b**: n= 12, **c**: n= 14, **d**: n= 15,
e: n= 16, **f**: n= 18, **g**: n= 20, **h**: n= 22



5

Figure 1. Structures of Immunosuppressants

Chemistry: Racemic compounds **4a-h**[7] were synthesized in the same manner as described in the previous paper[6].

Compounds (*R*)- and (*S*)-**5** were prepared by resolution of the racemate (Scheme 1). Treatment of racemic **5**[6] with (*S*)-(+)-MTPA chloride in the presence of Et_3N and *N*,*N*-dimethylaminopyridine afforded a diastereomeric mixture of the *N*,*O*-di-(*R*)-MTPA derivative. The mixture was purified by preparative HPLC to give **6** and **7**. Methanolysis of **6** and **7** with NaOMe afforded (*R*)-**5** {$[\alpha]_D$ - 0.81 (*c* = 1.73 in $CHCl_3$)} and (*S*)-**5** {$[\alpha]_D$ + 0.52 (*c* = 1.88 in $CHCl_3$)}, respectively. The absolute configurations of these compounds were confirmed by means of the modified Mosher's method[8].



Scheme 1: (a) (*S*)-MTPA-Cl, Et_3N, DMAP. (b) preparative HPLC. (c) NaOMe, MeOH



Scheme 2: (a) $Ph_3P^+C_{n-1}H_{2n-1}Br^-$, KHMDS. (b) 4 N HCl. (c) 10% Pd-C, H_2. (d) MPM-Cl, NaH. (e) 90% AcOH aq, LiCl. (f) SO_3-pyr, Et_3N. (g) DDQ.

Compounds (*R*)- and (*S*)-**4** were synthesized by starting from L-serine as shown in Scheme 2. The known compounds **8**[9a] and **9**[9a,b] were prepared. Wittig reaction of **9** with alkyltriphenylphosphonium bromide in the presence of KHMDS afforded the condensation product **10**. Treatment of **10** with 4 N HCl followed by reduction with H_2/10 % Pd-C afforded (*R*)-**4** {**4c**: $[\alpha]_D$ - 3.7 (*c* = 0.4 in MeOH), **4f**: $[\alpha]_D$ - 3.5 (*c* = 0.4 in MeOH)}. Treatment of **8** with *p*-

methoxybenzyl chloride (MPM-Cl) in the presence of NaH followed by deprotection of the acetonide with acetic acid afforded the reverse-configuration alcohol **11**. Compound **11** was oxidized with SO_3-pyridine to give the aldehyde **12**, which was converted into the olefin **13** by Wittig reaction. Deprotection of the *p*-methoxybenzyl group in **13** with DDQ followed by hydrogenation gave the saturated alcohol, which was treated with 4 N HCl to furnish (*S*)-**4** {**4c**: $[\alpha]_D$ + 1.6 (c = 0.46 in MeOH), **4f**: $[\alpha]_D$ + 4.7 (c = 0.42 in MeOH)}.

Results and Discussion: The effect of the racemic 2-aminoalcohols (**4a-h**) on the mouse allogeneic mixed lymphocyte reaction (MLR)[1b] was examined. Figure 2 shows the IC_{50} values of **4a-h** versus their side-chain length. The 2-aminoalcohols (**4a-h**) showed a bell-shaped relationship on the graph between the activity and side-chain length. In this series, 2-aminohexadecanol (**4c**) was the most potent compound.



Figure 2. Effect of 2-Aminoalcohols on Mouse Allogeneic MLR

Next, the IC_{50} values of the (*R*)- and (*S*)- isomers of **4c**, **4f** and **5** on mouse allogeneic MLR were measured to investigate the relationship between the activity and the configuration at C-2 in the 2-aminoalcohol (Table). The (*R*)-isomers were more potent than the (*S*)-isomers. In particular, (*R*)-**4c** possessed the most potent activity among the isomers and showed similar activity to **3** (IC_{50} = 67.4 nM).

Table

	MLR IC_{50} (nM)		
	racemate	(*R*)-isomer	(*S*)-isomer
4c	98.3	68.8	137
4f	867	533	1390
5	211	108	427

(*R*)-2-Aminoalcohol has the same D-configuration as natural sphingosine, the biosynthesis of which is inhibited by **1**[10]. On the other hand, D,L-2-amino-4-octadecen-1-ol did not inhibit the incorporation of serine into sphingolipids[11]. Since immunosuppressively active 2-aminoalcohol is structurally similar to D,L-2-amino-4-octadecen-1-ol, it also should not inhibit the incorporation of serine into sphingolipids. We anticipate that the immunosuppressive activity of 2-aminoalcohol can be caused by inhibition of same biological action of sphingosine or a derivative, such as sphingosine-1-phosphate.

References and Notes

1. (a) Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y.; Okumoto, T. *Abstracts of Papers of 17 th IUPAC International Symposium on the Chemistry of Natural Products*, New Delhi, p.68, **1990**. (b) Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y.; Okumoto, T. *J. Antibiotics* **1994**, *47*, 208.
2. (a) Kluepfel, D.; Bagli, J.; Baker, H.; Charest, M. P.; Kudelski, A.; Sehgal, S. N.; Vezina, C. *J. Antibiotics* **1972**, *25*, 109. (b) Bagli, J. F.; Kluepfel, D.; Jacques, M. St. *J. Org. Chem.* **1973**, *38*, 1253.
3. (a) Aragozzini, F.; Manachini, P. L.; Craveri, R.; Rindone, B.; Scolastico, C. *Tetrahedron* **1972**, *28*, 5493. (b) Banfi, L.; Beretta, M. G.; Colombo, L.; Gennari, C.; Scolastico, C. *J. C. S. Chem. Commun.* **1982**, 488. (c) Banfi, L.; Beretta, M. G.; Colombo, L.; Gennari, C.; Scolastico, C. *J. Chem. Soc. Perkin Trans. I* **1983**, 1614.
4. Fujita, T.; Yoneta, M.; Hirose, R.; Sasaki, S.; Inoue, K.; Kiuchi, M.; Hirase, S.; Adachi, K.; Arita, M.; Chiba, K. *BioMed. Chem. Lett.* **1995**, *5*, 847.
5. Adachi, K.; Kohara, T.; Nakao, N.; Arita, M.; Chiba, K.; Mishina, T.; Sasaki, S.; Fujita, T. *BioMed. Chem. Lett.* **1995**, *5*, 853.
6. Fujita, T.; Hirose, R.; Hamamichi, N.; Kitao, Y.; Sasaki, S.; Yoneta, M.; Chiba, K. *BioMed. Chem. Lett.* **1995**, *5*, 1857.
7. **4a-c**: Beger, J.; Poschmann, C.; Thomas, I. *J. Prakt. Chem.* **1984**, *326*, 519. **4e**: Minsner, B. I.; Orlova, E. G.; Zvonkova, E. N.; Evstigneeva, R. P. Zh. Org. Khim. **1973**, *9*, 2010. **4f**: Prostekin, M; Castek. A.; Cosovic, C.; Gospocic, Lj.; Jandric, Z.; Kljaic, K.; Ondrusek, V.; Weinert, M. *Bull. Sci., Cons. Acad. Sci. Arts RSF Yougoslavie, Sect. A* **1974**, *19*,1. **4d**, **g**, **h** are new compounds, and gave satisfactory analytical and spectroscopic data in accord with their assigned structures.
8. $\Delta\delta = \delta_S - \delta_R$ for the (*R*)- and (*S*)-MTPA amides derived from (*R*)- and (*S*)-**5**: (*R*)-**5**; 1-H_2 (-0.0299), 3-H_2 (+0.0318), 4-H_2 (+0.103). (*S*)-**5**; 1-H_2 (+0.0231), 3-H_2 (-0.0342), 4-H_2 (-0.104).
9. (a) Garner, P.; Park, J.-M. *J. Org. Chem.* **1987**, *52*, 2361. (b) Torisawa, Y.; Motohashi, Y.; Ma, J.; Hino, T.; Nakagawa, M. *Tetrahedron Lett.* **1995**, *36*, 5579.
10. Miyake, Y.; Kozutsumi, Y.; Nakamura, S.; Fujita, T; Kawasaki, T. *Biochem. Biophys. Res. Commun.* **1995**, *211*, 396.
11. Echten, G. v.; Birk, R.; Brenner-Weiss, G.; Schmidt, R. R.; Sandhoff, K. *J. Biol. Chem.* **1990**, *265*, 9333.

(*Received in Japan* 21 *August* 1996; *accepted* 8 *October* 1996)